2,088,937 Shares in Protara Therapeutics, Inc. (NASDAQ:TARA) Purchased by Toronto Dominion Bank

Toronto Dominion Bank purchased a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 2,088,937 shares of the company’s stock, valued at approximately $11,030,000. Toronto Dominion Bank owned 0.10% of Protara Therapeutics as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. RA Capital Management L.P. boosted its holdings in shares of Protara Therapeutics by 78.9% in the 4th quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock worth $17,952,000 after acquiring an additional 1,500,000 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Protara Therapeutics during the 4th quarter valued at $11,938,000. Adage Capital Partners GP L.L.C. bought a new position in Protara Therapeutics in the 4th quarter valued at $11,880,000. Blackstone Inc. acquired a new position in Protara Therapeutics in the fourth quarter worth $8,870,000. Finally, Integral Health Asset Management LLC bought a new stake in shares of Protara Therapeutics during the fourth quarter worth $7,392,000. 38.13% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the completion of the sale, the insider now owns 98,861 shares of the company’s stock, valued at approximately $447,840.33. This trade represents a 17.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.40% of the stock is owned by insiders.

Protara Therapeutics Trading Up 1.8%

Shares of TARA opened at $3.48 on Wednesday. The stock has a market capitalization of $134.27 million, a price-to-earnings ratio of -1.23 and a beta of 1.73. Protara Therapeutics, Inc. has a 12 month low of $1.60 and a 12 month high of $10.48. The firm has a fifty day simple moving average of $3.90 and a 200 day simple moving average of $4.14.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.18. As a group, research analysts predict that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

TARA has been the subject of a number of research analyst reports. Lifesci Capital began coverage on Protara Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research report on Monday, April 28th. Scotiabank started coverage on shares of Protara Therapeutics in a research note on Wednesday, April 16th. They issued a “sector outperform” rating and a $12.00 target price for the company. Finally, Cantor Fitzgerald started coverage on shares of Protara Therapeutics in a research note on Friday, March 14th. They set an “overweight” rating on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $20.40.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.